Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Research & Development: 2009-2024

Historic Research & Development for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $12.0 million.

  • Gyre Therapeutics' Research & Development fell 14.85% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 2.21%. This contributed to the annual value of $12.0 million for FY2024, which is 12.74% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Research & Development of $12.0 million as of FY2024, which was down 12.74% from $13.8 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Research & Development ranged from a high of $68.9 million in FY2021 and a low of $12.0 million during FY2024.
  • Its 3-year average for Research & Development is $14.2 million, with a median of $13.8 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 30.04% in 2021, then crashed by 75.78% in 2022.
  • Gyre Therapeutics' Research & Development (Yearly) stood at $53.0 million in 2020, then skyrocketed by 30.04% to $68.9 million in 2021, then crashed by 75.78% to $16.7 million in 2022, then decreased by 17.42% to $13.8 million in 2023, then fell by 12.74% to $12.0 million in 2024.